Because family physicians are assum...

Because family physicians are assuming a greater part in caring for patients with cancer, an understanding of tumor markers is becoming increasingly important. These soluble indivisible particles in the blood are usually glycoproteins exposeed by monoclonal antibodies. Each tumor marker has a variable profile of usefulness for screening, determining diagnosis and prognosis, assessing answer to therapy, and monitoring for cancer recurrence

This article describes the use of frequent tumor markers in primary care practice. Particular emphasis is given to when these touchstones should be ordered and to everyday factors that influence the interpretation of tumor marker levels

part of Tumor Markers

Screening proofs require high sensitivity to find early-stage disease. These tests also must have sufficient specificity to screen patients with false-positive results from unwarranted diagnostic evaluations.

To date, no tumor marker has demonstrated a survival benefit in randomized controll trials of screening in the general population. Nevertheless, tumor markers can play a crucial part in detecting disease and assessing answer to therapy in selected collections of patients. In monitoring patients for disease return tumor marker levels should be determined solely when there is a potential for meaningful treatment.

Normalization of tumor marker values may indicate remedy despite radiographic evidence of persistent disease. In this circumstance, the residual tumor is not rarely nonviable. Conversely, tumor marker plains may rise after effective treatment (possibly related to enclosed space lysis), but the increase may not portend treatment failure. However, a consistent increase in tumor marker of the same heights coupled with lack of clinical improvement, may indicate treatment failure. Residual elevation after definitive treatment usually indicates persistent disease. Following tumor marker rejoinder is particularly useful when other evidence of disease is not readily accessible.

Cancer Antigen 2729

Cancer antigen (CA) 2729 is a monoclonal antibody to a glycoprotein (MUC1) that is near on the apical surface of normal epithelial confined apartments CA 27.29 is highly associated with breast cancer, although on a levels are elevated in several other malignancies (Table 1) (1-14) CA 2729 also can be construct in patients with benign disorders of the breast, liver, and kidney, and in patients with ovarian pouchs However, CA 27.29 levels higher than 100 units by means of mL are rare in benign conditions. (1)

Because of superior sensitivity and specificity, CA 2729 has supplanted CA 15-3 as the preferr tumor marker in breast cancer. The CA 2729 of the same height is elevated in approximately common third of women with early-stage breast cancer (stage I or II) and in pair thirds of women with late-stage disease (stage III or IV). (2) CA 2729 lacks predictive value in the earliest stages of breast cancer and thus has no character in screening for or diagnosing the malignancy.

Disagreement exists about the ability of CA 2729 to discover asymptomatic recurrence after curative treatment. common trial (1) in patients at high risk for resort of breast cancer (stage II or III) lay the foundation of that CA 27.29 was highly specific and sensitive in detecting preclinical metastasis. The average time from initial elevation of CA 2729 to attack of symptoms was five month Because CA 2729 testing may lead to alert imaging of probable sites of metastasis, it may be possible to decrease morbidity from one side earlier institution of therapy.

Carcinoembryonic Antigen

Carcinoembryonic antigen (CEA), an oncofetal glycoprotein, is exhibited in normal mucosal cells and overexpress in adenocarcinoma, especially colorectal cancer (Table 1) (1-14) CEA elevations also fall out with other malignancies. Non-neoplastic conditions associated with elevated CEA flats include cigarette smoking, peptic imposthume disease, inflammatory bowel disease, pancreatitis, hypothyroidism, biliary obstruction, and cirrhosis. plains exceeding 10 ng per mL are rarely appropriate to benign disease. (3)

Fewer than 25 percent of patients with disease confined to the colon have an elevated CEA plain Sensitivity increases with advancing tumor stage: CEA values are elevated in approximately 50 percent of patients with tumor extension to lymph nodes and 75 percent of patients with distant metastasis. (4) The highest values (above 100 ng through mL) occur with metastasis, (15) although poorly differentiated tumors are les likely to breed CEA. (4)

CEA is not useful in screening for colorectal cancer or in the diagnostic evaluation of an undefined illness. A CEA of the same height should be ordered only after malignancy has been confirmed. CEA of the same heights typically return to normal within four to six weeks after fortunate surgical resection. (3)

The major part for CEA levels is in following patients for relapse after intended curative treatment of colorectal cancer. When patients with a normal preoperative CEA flat have cancer recurrence, CEA elevation is a sign in nearly common half of them. (4)